On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE ... at risk of rapid disease progression. In ...
The FDA has approved Alnylam’s gene silencing drug ... As the kidney function worsens, oxalate can build up and damage other organs including the heart, bones and eyes. The disease is also ...
Novartis NVS ... from the U.S. Food and Drug Administration for a treatment to bring down elevated levels of protein in the urine of adults who have a rare kidney disease. The approval follows ...
The company had focused its resources on Filspari’s launch in IgAN after the US FDA snubbed the therapy in another rare ...
16 (UPI) --The Food and Drug ... with kidney issues Ozempic and Wegovy can prevent heart problems in overweight and obese people, particularly if they also suffer from kidney disease, a new ...
The common, but serious, complication of chronic kidney disease is often seen in patients on hemodialysis. Upacicalcet is already approved for SHPT in Japan, where the drug “performed ...
Novartis’ $3.2 billion deal for Chinook Therapeutics gave the Swiss Big Pharma such a taste for kidney disease-focused ... iptacopan scored FDA approval in IgAN. That drug, marketed as Fabhalta ...
Incyte and Syndax will seek approval to launch two smaller vial sizes following the FDA's approval of Niktimvo (as a 50mg vial). Following FDA approval of the new vial sizes, the companies ...
Aug. 21, 2024 – The FDA has approved a new initial treatment for advanced non-small-cell lung cancer after clinical trials showed patients lived longer without disease progression, compared to ...
With the Food and Drug Administration’s clearance ... better protection against currently circulating variants,” said FDA vaccine chief Dr. Peter Marks. The agency’s decision came a bit ...
The FDA approved Livdelzi under accelerated approval ... PBC is a rare, chronic, autoimmune disease of the bile ducts that affects approximately 130,000 Americans, primarily women, and can cause ...
